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OBJECTIVE — To test whether the frequency of human enterovirus RNA in fecal samples
collected monthly from early infancy was associated with development of multiple islet autoan-
tibodies in children with the highest risk HLA genotype.
RESEARCH DESIGN AND METHODS — Individuals carrying the HLA DRB1*0401-
DQA1*03-DQB1*0302/DRB1*03-DQA1*05-DQB1*02 genotype were identiﬁed at birth and fol-
lowed with monthly stool samples from age 3 to 35 months. Blood samples taken at age 3, 6, 9,
and 12 months and then annually were tested for autoantibodies to insulin, GAD 65 and IA-2.
Among911children,27developedpositivityfortwoormoreisletautoantibodiesintwoormore
consecutive samples (case subjects). Two control subjects per case subject were matched by
follow-up time, date of birth, and county of residence. Stool samples were analyzed for entero-
virus with a semiquantitative real-time RT-PCR.
RESULTS — The frequency of human enterovirus RNA in stool samples from case subjects
before seroconversion (43 of 339, 12.7%) did not differ from the frequency in control subjects
(94 of 692, 13.6%) (P  0.97). Results remained essentially unchanged after adjustment for
potential confounders, restriction to various time windows before seroconversion, or infections
in the 1st year of life or after inclusion of samples collected after seroconversion. There was no
difference in the average quantity of enterovirus RNA or in the frequency of repeatedly positive
samples.TheestimatedrelativeriskforisletautoimmunityperenterovirusRNA–positivesample
during follow-up (nested case-control analysis) was 1.12 (95% CI 0.66–1.91).
CONCLUSIONS — There was no support for the hypothesis that fecal shedding of entero-
viral RNA is a major predictor of advanced islet autoimmunity.
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H
uman enteroviruses have been con-
sidered as possible environmental
triggers or accelerators of islet auto-
immunityleadingtotype1diabetes(1,2).
Theyhavebeenobservedmorefrequently
in patients in whom type 1 diabetes was
recently diagnosed compared with con-
trol subjects, and there is also evidence of
the virus in the pancreata of subjects who
died shortly after disease onset (3). How-
ever,aninterpretationofvirusoccurrence
at or shortly after diagnosis is difﬁcult
with respect to type 1 diabetes pathogen-
esis, because the autoimmune process
starts months to years before its clinical
manifestation.
Potential causal relations between in-
fections and development of islet autoim-
munity are best assessed in longitudinal
birthcohortstestingviralinfectionsatfre-
quent intervals before and during the de-
velopment of islet autoimmunity. Five
such studies, including between 11 and
41casesofisletautoimmunity,havesofar
published results on enterovirus using
various methods and testing strategies
(more details are found in CONCLUSIONS).
The evidence for involvement of entero-
virus in type 1 diabetes pathogenesis
comes predominantly from the Finnish
population (4–6), whereas a study from
Colorado (7) and one from Germany (8)
did not ﬁnd any signiﬁcant association.
Inviewoftheseconﬂictingresults,we
aimed to test whether the presence of hu-
manenterovirusinmonthlyfecalsamples
predicted development of repeated posi-
tivity for two or more diabetes-associated
islet autoantibodies in children with the
HLA genotype conferring the highest risk
for type 1 diabetes.
RESEARCH DESIGN AND
METHODS— The children prospec-
tivelyobservedinthisstudyparticipatein
the Norwegian cohort entitled “Environ-
mental Triggers of Type 1 Diabetes: The
MIDIA Study.” The cohort was identiﬁed
atbirthfromthegeneralpopulationbased
on genetic testing for the HLA genotype
conferring the highest genetic risk of type
1 diabetes, DRB1*0401-DQA1*03-
DQB1*0302/DRB1*03-DQA1*05-
DQB1*02. Between 2001 and 2006, 911
children were included into the cohort.
All subjects were followed up with stool
samples, blood samples for autoantibody
screening, and structured questionnaires.
The study was approved by the Regional
Committee for Medical Research Ethics
and the Norwegian Data Inspectorate.
Blood samples taken at ages 3, 6, 9,
and 12 months and every 12 months
thereafterwereprocessed,andtheplasma
was tested for autoantibodies against
GAD 65, protein tyrosine phosphatase
IA-2, and insulin, using radiobinding as-
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Mailed questionnaires were administered
at the same intervals. If a plasma sample
was found to be positive for one autoan-
tibody, the child was retested every 6
months; if a sample was positive for two
or three antibodies, the child was retested
every 3 months. The end point for this
study, islet autoimmunity, was deﬁned as
positivity for two or more islet autoanti-
bodies in two or more consecutive sam-
ples. Type 1 diabetes was diagnosed
according to the World Health Organiza-
tion criteria.
By December 2008, 27 of the 911
children in the cohort had reached the
end point and were assigned as case sub-
jects. The median age at onset of islet au-
toimmunitywas12.0months(range5.4–
37.4 months). Of the 27 case children,
diabetes was diagnosed in 10 by 1 Sep-
tember 2009, at a median age of 23.1
months(8.7–54.2months).Thetimingof
autoantibody seroconversion and age at
diagnosis for each of the case subjects is
shown in supplementary Table 1 (avail-
able in an online appendix at http://care.
diabetesjournals.org/cgi/content/full/
dc10-1413/DC1).
Two control subjects were randomly
assignedpercasesubject,matchedforthe
length of follow-up (at least as long as the
timewhenthecorrespondingcasesubject
developed multiple islet autoantibodies),
date of birth within 1 month (tolerating
up to 3 months if necessary), and
county of residence (tolerating closest
neighboring county if necessary). Chil-
dren were ineligible as control subjects if
they were repeatedly positive for one or
more islet autoantibodies during follow-
up. One control subject was transiently
positive for a single autoantibody before
the end point in the respective case sub-
ject; otherwise no control subjects devel-
oped positive autoantibodies (even after
their case subject reached the end point).
Data from one control child (matching
group27)aremissingbecausetheparents
later withdrew the child from the study
and refused any use of the collected data.
To test for enterovirus infections, we
used stool samples obtained by the par-
ents; they collected stool samples from
their children every month from 3 to 35
months of age. These were sent by mail to
our central laboratory, with a median
transit time of 3 days. Parents also kept
recordsofsymptomsofinfectioninstruc-
tured questionnaires. Of 704 planned
blood samples, 637 were taken (91%);
2,173 of 2,482 scheduled stool samples
(88%) and 492 of 547 questionnaires
were received (90%). The median dura-
tion of follow-up with stool samples was
28 months (range 7–35 months). The
characteristics of the study participants
are shown in Table 1.
Processing and molecular testing of
stool samples
The processing and testing of stool sam-
ples in this study were described earlier
(10). In brief, the samples were received
by postal service, diluted, and centri-
fuged. The supernatants were frozen at
80°C until copuriﬁcation of RNA and
DNA. The extraction protocol used the
96-well QIAamp plates vacuum-
processed under the QIAamp Viral RNA
Mini protocol (Qiagen, Hilden, Ger-
many). West Nile virus Armored RNA
(Asuragen, Austin, TX) was added in a
constant quantity to the lysis buffer,
which was used in the ﬁrst step of the
protocol. This exogenous internal control
was used to monitor the success of RNA
extraction and detection. Testing for hu-
man enterovirus RNA was performed in
duplicate in 20-l-volume one-step real-
timeRT-PCRwithaprimer-probecombi-
nation speciﬁc for the conserved 5-
untranslated region of human
enteroviruses. This combination does not
react with the rhinovirus species. Serial
dilutions of enterovirus Armored RNA
(Asuragen) were used to construct a sev-
en-point standard curve from 24 to 10
5
copies/l. The threshold of positivity
usedinthisstudywassetto100copies/l
RNA,aquantitythatcouldbeconsistently
and reliably detected.
Statistical analysis
To optimize the use of information in re-
peated samples collected from each indi-
vidual, we compared the percentage of
enterovirus RNA–positive samples col-
lected from case subjects with those col-
lected from control subjects, and tested
this result using a mixed-effect logistic re-
gressionmodelwithrandominterceptfor
each individual to account for potential
intraindividual correlation (clustering) in
risk of enterovirus positivity (xtmelogit in
Stata 11). The primary analysis involved
only samples collected up to seroconver-
sion for the case subjects and the corre-
sponding age in the matched control
subjects. In case subjects who ﬁrst tested
positive for a single autoantibody, this
ﬁrstoccurrenceofautoantibodypositivity
was regarded as the onset of autoimmu-
nity. The estimated odds ratio (OR) (with
95% CI) from this model is interpreted as
the odds that a fecal sample is positive for
enteroviral RNA given that it came from a
child who later developed islet autoim-
munity, relative to the odds that a sample
is enterovirus-positive given that it came
fromacontrolchild.Planned(secondary)
subgroup analyses involved time win-
Table 1—Characteristics of the case subjects and control subjects in this study
Case subjects Control subjects
n 27 53
Age at onset of islet autoimmunity (months)* 12.1 (5–37) 12.3 (5–37)
Female sex 17 (63) 23 (43)
No. of other children in the family (siblings, half-
siblings, step siblings)
None 5 (18.5) 16 (30.2)
1 22 (81.5) 37 (69.8)
First-degree relative with diabetes
None 17 (63) 50 (94.3)
Yes, of that 10 (37) 3 (5.7)
Sibling only 3 0
Father only 3 2
Mother only 2 1
Multiple family members 2 0
Progression from islet autoimmunity to type 1 diabetes
Yes 10 None
Stool samples
Total 627 1,417
Before development of islet autoimmunity* 339 692
Data are median (range), n (%), and n. *For matched control subjects: before the age at which the corre-
sponding case subject seroconverted for islet autoantibodies.
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version in case subjects (and
corresponding ages in matched control
subjects), samples collected before 1 year
of age, and samples collected after sero-
conversion. We also adjusted for other
variables by including them in the regres-
sion model, as reported in RESULTS. In sep-
arate analyses only the ﬁrst enterovirus
RNA-positive samples among series of
two or more consecutively positive sam-
ples was counted, assuming that they
were part of the same infectious episode.
We also analyzed the data according
to a formal nested case-control study de-
sign using conditional logistic regression
(accountingforthematcheddesignwitha
ﬁxed intercept for each matching group),
modeling the cumulative number of en-
terovirus RNA–positive fecal samples be-
foreseroconversion(groupedas0,1,2,or
3) as the exposure variable. With the
given study design, the measure of asso-
ciation from this analysis is interpreted as
the relative risk of islet autoimmunity per
increase in cumulative number of entero-
virus RNA–positive samples, with a cor-
responding 95% CI.
RESULTS
Frequency of human enterovirus
before development of autoimmunity
ThefrequencyofhumanenterovirusRNA
in stool samples before the development
of islet autoimmunity did not differ be-
tween case subjects (12.7%) and control
subjects (13.6%). Results were similar
even after adjustment for age, sex, month
of sampling, year of sample, number of
siblings, breastfeeding, and ﬁrst-degree
relatives with type 1 diabetes (Table 2).
Likewise, no association was seen when
only infections before 12 months of age
(OR 1.02 [95% CI 0.51–2.04]) or various
time windows before seroconversion in
case subjects were analyzed: with a
6-month window, the frequency was 20
of 142 (14.1%) in case subjects vs. 42 of
308 (13.6%) in control subjects (1.05
[0.54–2.04]) and with a 12-month win-
dowthefrequencywas31of214(14.5%)
in case subjects vs. 62 of 454 (13.7%) in
control subjects (1.09 [0.62–1.92]). The
use of infectious episodes rather than
number of positive stool samples (i.e.,
consecutive positive samples were
deemed as a single episode) did not ap-
preciably alter the above ﬁgures. The re-
sults were similar when a conditional
logistic regression model estimating the
OR per increase in infections before de-
velopment of islet autoimmunity was
used (OR 1.12 [0.66–1.91]).
Quantity of human enterovirus RNA
The effect of viral load was assessed by
dividingthepositivityintotwocategories:
low to moderate (quantity of 100–9,999
enterovirus copies/l RNA) and high
(10,000 enterovirus copies/l RNA).
No association with islet autoimmunity
was found in this type of analysis (Table
3).Inthe43enterovirus-positivesamples
from the preautoimmunity period among
case subjects, the median estimated hu-
man enterovirus quantity was 18,000
copies/l RNA compared with a median
of 12,000 copies/l RNA among 94 en-
terovirus-positive samples from matched
control subjects from the corresponding
periods (Mann-Whitney nonparametric
testP0.37).Similarresultswereseenin
the samples collected after the onset of
autoimmunity. Among the 30 new en-
terovirus episodes during the preautoim-
mune period of case subjects, 13 (43.3%)
were followed by at least one additional
consecutive enterovirus-positive sample,
compared with 29 of 65 (44.6%) among
the control subjects (
2 test P  0.73).
Occurrence of human enterovirus
during the whole observation period
In total, we tested 2,044 stool samples
from the case subjects (627) and control
subjects (1,417) in the study. Human en-
terovirus was detected in 80 of 627
(12.8%) samples from case subjects and
210 of 1,417 (14.8%) samples from con-
Table 2—Frequency of human enterovirus fecal samples collected before islet autoimmunity
Case
subjects
Control
subjects
OR (95% CI)*
Unadjusted Adjusted†
n 27 53
Enterovirus RNA
Negative samples 296 598 1.00 (reference) 1.00 (reference)
Positive samples 43 (12.7) 94 (13.6) 1.01 (0.59–1.72) 1.09 (0.61–1.96)
Total 339 692
New enterovirus infection
episode
No 296 598 1.00 (reference) 1.00 (reference)
Yes 30 (9.2) 65 (9.8) 0.94 (0.59–1.52) 0.92 (0.54–1.57)
Total‡ 326 663
Data are n, n (%), and ORs (95% CI). *Estimated from logistic mixed-effects logistic regression models with
random intercept for each subject to control for intraindividual correlation (no signiﬁcant random intercept
inmodelforenterovirusepisodes,buthighlysigniﬁcantinmodelforenteroviruspositivity).Theunadjusted
OR in ordinary logistic regression ignoring intraindividual correlation in infections was 0.92; ‡Adjusted for
sex, calendar month of sample collection, year of sample collection (2001–2003, 2004–2006, or 2007–
2008),age(continuous),numberofsiblings(0vs.1),breast-feeding,andﬁrst-degreefamilyhistoryoftype
1diabetes(yes/no);†Excludingconsecutivelypositivesamplesthatmayhavebeenpartofthesameinfectious
episode as in the previous positive sample.
Table 3—Semiquantitative testing of the stool samples: frequency of enterovirus infections
with high and low viral load in the children who subsequently developed repeated positivity of
multiple autoantibodies vs. matched control subjects who did not develop autoimmunity
Case subjects Control subjects
n 27 53
Enterovirus RNA-negative 296 598
Enterovirus RNA-positive, low-moderate quantity* 18 (5.3) 46 (6.6)
Enterovirus RNA-positive, high quantity* 25 (7.4) 48 (6.9)
Total 339 692
Enterovirus RNA-negative 296 598
New infection episode, low-moderate quantity* 11 (3.4) 31 (4.7)
New infection episode, high quantity* 19 (5.9) 34 (5.1)
Total† 326 663
Data are n or n (%). *Negative, 100 copies/ml enterovirus RNA; low-moderate quantity, 100–9,999
copies/ml enterovirus RNA; high quantity, ³10,000 copies/ml enterovirus RNA; †Excluding consecutively
positive samples that may have been part of the same infectious episode as in the previous positive sample.
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not differ between case subjects and con-
trol subjects (OR 0.84 [0.58–1.22]).
Looking only at samples taken after the
start of islet autoimmunity gave similar
results (0.74 [0.45–1.22]). Only 11 sub-
jects did not shed enterovirus in their
stool during their entire observation pe-
riod (4 case subjects and 7 control sub-
jects). The remaining children had
various numbers of positive monthly
samples, from only 1 (n  7) up to 8–9
(n  7). Infections and their distribution
over the observational period in case sub-
jectsandcontrolsubjectsofthe27match-
ing groups are shown in supplementary
Fig. 1 (available in an online appendix at
http://care.diabetesjournals.org/cgi/
content/full/dc10-1413/DC1).
Seasonal variation of infections
Therewasapronouncedseasonalityofin-
fections with a peak in autumn (October
with 27% positive samples) and a smaller
peak in July (with 24% positive samples)
andadipinMarch(with3%positivesam-
ples).SupplementaryFig.1showsseveral
episodesofincreaseddensityofinfections
that can be observed across the case-
control matching group. The occurrence
of infections was also age-dependent: a
rise was noted from the 5th to 9th month
of age and during the ﬁrst half of the 2nd
year of life.
Molecular typing of enterovirus
strains using partial VP1 sequencing
VP1 genotypes were determined for se-
lected positive samples (97 samples) to
distinguishprolongedinfectionswithone
strain against multiple consecutive infec-
tions. The distribution of the 17 different
serotypes found is shown in supplemen-
taryTable2(availableinanonlineappen-
dix).Becausethesequencedsampleswere
not representative of the whole case-
control dataset, direct comparison of the
serotype repertoire between case subjects
and control subjects was not possible. A
phylogenetic tree constructed from the
dataset is shown in supplementary Fig. 2
(available in an online appendix).
CONCLUSIONS — We tested en-
terovirus RNA in 2,000 monthly fecal
samplesfromchildrenwhodevelopedre-
peatedpositivityformultipleisletautoan-
tibodies and their matched control
subjects, all with a single HLA-DQ, -DR
genotype, conferring the highest risk of
type 1 diabetes. We found no evidence to
support a higher frequency of enterovirus
in case subjects than in control subjects
either before or after seroconversion for
islet autoantibodies. It must be kept in
mind that the study population consisted
only of very young children; thus, the
conclusions might not apply to older
individuals.
This study is the ﬁrst to use a quanti-
tative assay for testing the viral load, en-
ablingustodistinguishbetweenlow-and
high-quantity infections and follow the
dynamics of the viral load. Our cohort
includes only the highest risk HLA-DQ,
-DRgenotypeandisthusmoregenetically
restricted than previously reported stud-
ies. The generalizability of our results
might be questioned if the HLA genotype
inﬂuenced the risk of enterovirus infec-
tion and/or immune response. However,
preliminary results from our pilot study,
which also included a group without the
high-risk HLA genotype, indicated only a
moderate difference in frequency of fecal
enterovirusshedding(11).Toourknowl-
edge, none of the previous cohort studies
ofenterovirusandisletautoimmunityhas
found any signiﬁcant difference in associ-
ation depending on HLA genotype.
We have also used a strict deﬁnition
of islet autoimmunity, requiring repeated
positivity for two or three islet autoanti-
bodies, which is known to be strongly
predictiveoftype1diabetesingenetically
susceptible children. The number of case
subjects and sample size could indeed be
increased with a less strict deﬁnition of
autoimmunity. However, the power of
the study might actually decrease by in-
cluding subjects with milder autoimmu-
nity who are less likely to eventually
develop type 1 diabetes.
Regular monthly sampling from all
participants and high completeness are
important strengths, because shedding
duration is thought to be 	3–4 weeks
(12); the necessity of frequent stool sam-
pling is further supported by our earlier
study showing that excretion usually
lasted 3 months (13). Detection of viral
RNA in serum would probably underesti-
mate the true infection frequency, be-
cause enterovirus RNA is present in
serum for a much shorter period (12)
thanistheusualtimespanbetweenblood
samples.Ontheotherhand,itisprobable
that viremia reﬂects more closely the
spreading of the virus to the target organ,
so frequent sampling of both stool and
blood samples would be ideal.
Althoughtheserotypesdetectedwere
not representative for all samples, we ob-
served no preponderance of a strain, se-
rotype, or group in either case subjects or
control subjects. Several serotypes previ-
ously reported as possibly diabetogenic
(e.g., Coxsackie B) were observed both in
case subjects and in control subjects. Al-
though some types may seem to be more
prevalent, this is mostly due to repeatedly
positive stool samples from a small geo-
graphical area during a short period, re-
ﬂecting local epidemics.
Two previous studies assessed fecal
shedding of enterovirus RNA. The Finn-
ish Type 1 Diabetes Prediction and Pre-
vention (DIPP) study used equally
frequent sampling of stool as we did, re-
porting data from 12 case subjects with
islet autoimmunity and 53 control sub-
jects (14). The other study was the Diabe-
tes Autoimmunity Study in the Young
(DAISY) in Colorado, for which rectal
swabs were collected at longer intervals
(at ages 9, 12, 15, and 24 months and
then annually) from 26 case subjects and
39 control subjects (7). In both studies,
there was no signiﬁcant difference in the
frequency of fecal enterovirus RNA shed-
ding between case subjects with islet au-
toimmunity and control subjects, which
is consistent with our ﬁndings. However,
in contrast with our ﬁndings, the DIPP
study reported that samples from case
subjects were more frequently positive in
consecutive samples than were samples
from control subjects.
A publication from DAISY (7) and a
separate publication from the DIPP study
including 41 case subjects and 196 con-
trol subjects with 3- to 6-month sample
intervals (4) also analyzed enterovirus
RNAinserum.Inboththesestudiesthere
was no signiﬁcant difference in the fre-
quency of serum enterovirus RNA, but
when serum RNA and a series of entero-
virus antibodies were combined as indi-
cators of infection, there was a signiﬁcant
difference in the DIPP study, particularly
in the 6-month interval before serocon-
version in case subjects. Although we did
not assess enterovirus RNA or antibodies
in serum, no indication of a clustering of
infections before seroconversion was
found.
Two other Finnish studies reported a
signiﬁcant difference between case sub-
jects with islet autoimmunity and control
subjects in frequency of indicators of en-
terovirus infection in serum, namely the
Childhood Diabetes in Finland (DiMe)
study assessing 11 prediabetic siblings of
patients with type 1 diabetes and 34 au-
toantibody-negative control subjects (6),
and the Trial to Reduce IDDM in Geneti-
Enterovirus and islet autoimmunity
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casesubjectsand84controlsubjectsfrom
birth to 2 years of age (5). Note, however,
that enterovirus RNA in serum accounted
for 23% of the identiﬁed infections (in-
creases in enterovirus antibodies ac-
counted for the remaining) and that the
difference in enterovirus RNA was bor-
derline(not)signiﬁcant(14vs.8.4%,P
0.07). Finally, no signiﬁcant association
was found in the German BABYDIAB
study, which tested antibodies against
Coxsackie viruses in blood samples col-
lected at the age of 9 months and at 2, 5,
and 8 years in 28 case subjects with per-
sistent islet antibodies and 51 matched
control subjects (8).
None of the previous studies contra-
dicts our ﬁnding that fecal shedding of
enterovirus RNA in general does not
strongly predict islet autoimmunity. Al-
though moderate effects (OR 1.5–2.0)
cannot be ruled out from our data, the
95% CIs around the OR estimated from
our actual data suggest that strong associ-
ations(OR2)areunlikely.However,we
cannot exclude a possible role of a sub-
group of enterovirus infections (particu-
lar strains) perhaps inﬂuencing viremia
and ability to spread from the gut (the
primary site of replication) to the target
organ. This ability was seemingly un-
linked to the viral load or duration of gut
infections, as judged from our results.
Other relevant factors may potentially in-
ﬂuence the level and duration of viremia
and the ability to invade the islets and
their 
-cells.
Insummary,therewasnoevidenceto
supportamajorroleoffrequency,timing,
or quantity of fecal enterovirus shedding
inpredictionofadvancedisletautoimmu-
nityandnoevidencethatisletautoimmu-
nity predicted increased susceptibility to
fecal enterovirus shedding. Further re-
searchshouldbefocusedonthecharacter
ofviremiaandtheabilityofenterovirusto
invade the target pancreatic tissue in
much larger sample sets.
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